Iopromide Reactions 1680, p189 - 2 Dec 2017 Acute kidney injury: 2 case reports In a prospective study, two patients [ages and sexes not stated] were described, who developed acute kidney injury during treatment with iopromide [times to reactions onset not stated; not all outcomes stated]. The patients had a history of type 2 diabetes mellitus and renal impairment. Both patients were scheduled to undergo coronary angiography/percutaneous coronary intervention with or without simultaneous coronary sinus aspiration. The patients received IV sodium chloride before the coronary angiography and was continued for 24 hours. The patients also received acetylcysteine [N-acetylcysteine] for 24 hours prior and also on the day of the coronary angiography procedure. The coronary angiography was performed using the standard technique via the right femoral approach. A 100% undiluted non-ionic contrast namely, iopromide was injected manually. The dose of iopromide was limited to 5 mL/kg of body weight if not surpassing 300mL, divided by the serum creatinine level. Coronary sinus aspiration was performed along with each iopromide injection in one patient. The patient, who underwent coronary angiography using iopromide along with simultaneous coronary sinus aspiration developed iopromide- induced acute kidney injury and was managed conservatively till spontaneous recovery was achieved. The other patient, who underwent coronary angiography using iopromide without simultaneous coronary sinus aspiration developed iopromide-induced acute kidney injury requiring haemodialysis. Author comment: "One patient in the CSA group, compared with 9 patients in the control group, developed contrast-induced acute kidney injury Diab OA, et al. Efficacy and Safety of Coronary Sinus Aspiration During Coronary Angiography to Attenuate the Risk of Contrast-Induced Acute Kidney Injury in Predisposed Patients. Circulation: Cardiovascular Interventions 10: e004348, No. 1, Jan 2017. Available from: URL: CIRCINTERVENTIONS.116.004348 - Egypt 803284692 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 Reactions Weekly Springer Journals


Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
1 page

Loading next page...
1 Page
Springer International Publishing
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
Publisher site
See Article on Publisher Site


You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches


Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.



billed annually
Start Free Trial

14-day Free Trial